The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Fedratinib plus CC-486, an oral HMA, in accelerated-phase myelofibrosis: the FAMy trial
In this video, Haifa Kathrin Al-Ali, MD, University Hospital Halle, Halle, Germany, discusses the Phase I/II FAMy trial (DRKS00030348; EudraCT 2021-003650-23), which investigated the combination of fedratinib with the oral hypomethylating agent (HMA) CC-486 in patients with accelerated-phase myelofibrosis (MF). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
